27 - 28 November, 2018 | London Marriott Hotel Regents Park, London, United Kingdom

Effective IP Management and Monetisation Strategies

8:00 - 9:00 Morning Coffee, Registration, and IQPC Welcome

9:00 - 9:15 CHAIRMAN’S REMARKS & OPENING OF DAY TWO

Rachel Fetches - Partner, HGF London
img

Rachel Fetches

Partner
HGF London

9:15 - 9:45 IP Monetisation in the Life Sciences: A Broader Perspective

Jamie Kemler - VP, Intellectual Property Business Strategy, Stryker
An assessment of the various options available to your organisation with regards to monetisation,
How can you further monetize your IP assets through licensing, cross-licensing etc?
Focusing on licensing patents to start-ups, right of reference to clinical data, software and tools, and technology licenses outside of your core markets
Taking a broad view of un-used and non-core IP including trademarks and discontinued products opens up additional opportunities to monetize a life-science IP portfolio.
img

Jamie Kemler

VP, Intellectual Property Business Strategy
Stryker

An assessment of the various options available to your organisation with regards to monetisation,
How can you further monetize your IP assets through licensing, cross-licensing etc.?
How can Ocean Tomo empower Life Science IP’s, and how does this best suit Pharmaceutical companies
img

Ryan Zurek

Managing Director
Ocean Tomo

img

Dr Michael Täger

CEO
SET Asset Management GmbH

img

Susan Dunn

CEO
Harbour Litigation Fund

Providing a basic update on current procedures running within the European Patent Office
What are the bases of Early Certainty Programmes?
What can they offer Life Science companies? What do Life Science IP’s stand to gain?
img

Dr Dieter Tzschoppe

Director of Operations - Biotechnology / Pure and Applied Organic Chemistry
European Patent Office

11:00 - 11:30 MORNING BREAK & NETWORKING

Is there anything special about patenting antibodies?
Contested area of law – Pharmaceuticals moving away from chemical products and more towards biotech products
Previously, patents were granted generously, with broad scope – Since screening has improved, requirement to prove more defined antibodies to secure protection
How to overcome the issue of inventiveness?
img

Dr Sven Bostyn Lic.Jur., LLM, PhD

Associate Professor of Biomedical Innovation Law
Law Center for Advanced studies in Biomedical Innovation Law

12:00 - 12:30 Second medical use claims: An Overview and Criteria before the EPO

Dr Guido Pontremoli - Corporate IP Patent Director, Chiesi
Will contemplate the second medical use claims particularly before the EPO, in terms of case law
Explore the appropriate wording and plausibility when discussed in opposition or examination
Will  provide practical examples and strategies in order to be in compliance with the plausibility requirements particularly when the applicant files a patent application for SMU without in vivo data
Plausibility vs Speculation
img

Dr Guido Pontremoli

Corporate IP Patent Director
Chiesi

12:30 - 13:30 NETWORKING LUNCH

13:30 - 14:00 UPC & Brexit: Strategic Issues from an Industry Perspective

Francesco Macchetta - Director of Intellectual Property, Bracco
This session will cover the following topics:
Update on the status of UPC and its perspective entering into force
UK in the UPC post-Brexit
UPP (Unitary patent protection) in post-Brexit times
Anything more needed to prepare for it?
img

Francesco Macchetta

Director of Intellectual Property
Bracco

14:00 - 14:30 Complications of Supplementary Protection Certificates

Roya Ghafele - Executive Director, OxFirst
SPC’s are becoming an increasingly important means of extending the life of IP protection for biopharma and pharma drug products.
Will assess the new versus the old- looking into what the new system will looking and how it compares- as well as recent CJEU referrals. 
img

Roya Ghafele

Executive Director
OxFirst

14:30 - 15:30 INDUSTRY FOCUS GROUPS

In this interactive session, you will have the opportunity to deep-dive in to one specific topic, joining your peers in discussing challenges, developing strategy and sharing your thoughts with like-minded professionals.
 
Each person will have the opportunity to select and discuss one of the below topics for 45 minutes each, before a group spokesperson will be invited to share their thoughts collectively in the 15 minute wrap-up summary session. Please note all attendees will be asked to provide their preferences prior to the conference to help manage numbers onsite and to avoid disappointment on the day! 

Sessions available:
Emerging Challenges in Life Sciences IP: The Role of AI. 
When Competition and IP Law Collide – Ramifications of this Intersection
Chinese Market – Opportunities and Pitfalls

15:30 - 16:00 AFTERNOON BREAK & NETWORKING

16:00 - 16:30 Blockchain, AI and Big Data Analysis for the New Patent Ecosystem

Mei-Hsin Wang - CEO, BioMedical & Technology Application Association
Covering AI and Big Data Analysis for patent value and patent quality
How blockchain and Smart contract can change the patent ecosystem
Essential Standard Patent alliance management to be applied on block chain environment with smart contracts
Validation of AI and Big Data Analysis applied on Patent Value and Quality: ex: patents involved in Align vs Clear correct
How to face the IP challenges related to cyber-physical Patent Ecosystem?
img

Mei-Hsin Wang

CEO
BioMedical & Technology Application Association

16:30 - 17:00 Summary Session

An opportunity to wind-down, reflect on learnings, create next-steps and follow up activities and consolidate learnings throughout the last two days.
 Facilitated by the chairperson, this session will look at the tangible takeaways from today and the previous day, and call on your input to help form the basis for the post event report, to be shared with all attendees following the conference. 

17:00 - 17:15 CHAIRMAN’S CLOSING THOUGHTS & CLOSE OF CONFERENCE

Rachel Fetches - Partner, HGF London
img

Rachel Fetches

Partner
HGF London